Dave Muoio
During an earnings call yesterday, executives of the clinical trial technology company Medidata heralded a digital shift in novel drug investigations, announcing that the company’s virtual trial platform, Engage, will now be offered as part of its Clinical Cloud product, and that a virtual trial powered by the company’s technology and recruiting an estimated 15,000 or more participants is now underway.
Rockville, Maryland-based DrFirst, which is known for healthcare SaaS offerings ranging from medication management to clinical communications, has announced a relaunch of a mobile app designed to help physicians comply with state prescription drug monitoring program requirements when prescribing treatments.
Telehealth platform InTouch Health, North Carolina-based Mission Health, and Pennsylvania-based Jefferson Health have announced a partnership to collaborate on new telehealth solutions to improve care and reduce costs.
Following a soft launch last year, the chemoWave disease companion app has now been fully released for chemotherapy patients interested in better managing their care, symptoms, and side effects.
Stephen Friend, a key driver of Apple’s recent healthcare efforts, appears to have quietly left the company in November 2017, according to a LinkedIn profile in which he refers to himself as “an independent entrepreneur.
For years, there has been a growing movement to consider patients’ time outside of the healthcare system as a key determinant of their health.
With influenza running rampant and several other infections waiting in the wings, some may be interested in knowing whether a specific disease is common in their community.
Wellness program technology firm Vitality Group today announced the launch of its Gateway program, a series of partnerships that brings digital chronic care, mental health care, and other wellness offerings to its US corporate membership.
In-vitro fertilization-focused machine learning company Univfy has raised $6 million in Series A funding, according to a statement released today.
The Juvenile Diabetes Research Foundation (JDRF) and Massachusetts-based Cam Med, a company specializing in microfluidic-based drug delivery technologies, announced a partnership today focused on development of a thin, flexible, patch-based insulin pump for artificial pancreas systems.